Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Editorial Boards
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Editorial Boards
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Resident & Fellow Section

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
American Academy of Neurology Journals
Home
  • Subscribe
  • My Alerts
  • Log in
Site Logo

Alzheimer's disease

  • Aducanumab Resources

    The US Food and Drug Administration (FDA) announced on June 7, 2021, the approval of aducanumab (Aduhelm). The drug was approved under the Accelerated Approval pathway, one of the alternative drug approval pathways.

    In addition to our latest articles on Alzheimer disease, Neurology has included a list of aducanumab resources on this page to help our members stay informed on the current landscape of the new Alzheimer disease drug.

      Featured Editorials and Viewpoints

     

     

    Aducanumab: Making Sense of the Cents
    Gregory S. Day, MD, MSc, MSCI, FAAN

    Inevitably, the assumptions that guide cost-effectiveness calculations for any one patient will be as diverse and unique as the patient in question. Thus, we must be prepared to guide our patients with early symptomatic AD in this decision-making process, helping them to weigh uncertain benefits, risks, and costs associated with the use of aducanumab and other forthcoming treatments for AD. [Read Article]

    Practical Considerations in the Administration of Aducanumab for the Neurologist
    Katherine Coerver, Melissa M Yu, Anelyssa D'Abreu, Marc Wasserman, Kavita Nair

    The decision by the FDA to approve aducanumab remains controversial and its administration will pose many challenges that will be new to neurologists, despite extensive experience with prior intravenous medications. [Read Article]

    Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
    Winston Chiong, Benjamin David Tolchin, Richard J. Bonnie, et al.

    Neurologists, patients and families will face ethical challenges given the incomplete data available to guide aducanumab prescribing, the prospect of worrisome financial conflicts of interest, and the costs and practical burdens that using aducanumab will impose on patients and families. Neurologists facing these challenges will be guided best by established ethical principles that they can apply, in turn, to transparently counsel patients and their families. [Read Article]

    Aducanumab for Dementia
    Brian C. Callaghan

    In contrast to the unknown and unlikely efficacy, aducanumab has known serious side effects and high costs. Given the large downsides and unclear and unlikely benefits, I strongly support ICER’s report that states that there is insufficient evidence to support approval of aducanumab without further studies. [Read Article]


    Clinical Efficacy, Drug Safety and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Linda A. Hershey, Rawan Tarawneh

    ...the patient and their caregivers need to understand that the clinical benefits of aducanumab are small and that more data will be needed in the future to determine whether these benefits are clinically or functionally meaningful to patients. [Read Article]


    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
    Stephen Salloway, Jeffrey Cummings

    Aducanumab opens a new era in AD research and care and provides a foundation for development of progressively better therapies. [Read Article]


    Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    David S. Knopman, Joel S. Perlmutter

    On the one hand, neurologists want to offer hope. Yet, aducanumab’s benefits are meager, if even present and there are non-trivial risks of side effects. [Read Article]

     

     

      Aducanumab Podcasts












    View All Episodes

Latest Articles

  • Research Article
    Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology
    Breton M. Asken, Jeremy A. Tanner, Lawren VandeVrede, et al.
    Neurology May 16, 2022
  • Research Article
    Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia
    Bryn Farnsworth von Cederwald, Maria Josefsson, Anders Wåhlin, et al.
    Neurology April 20, 2022
  • Editorial
    Exercise and Brain HealthUntangling the Links
    Vijay K Ramanan, Jonathan Graff-Radford
    Neurology April 13, 2022
  • Research Article
    Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment
    Zonghua Li, Michael G. Heckman, Takahisa Kanekiyo, et al.
    Neurology March 21, 2022
Show more
Advertisement
  • AAN Aducanumab Resources

    Brain made of gears that are falling away.

    • AAN Aducanumab Resource Center
    • How to Talk to Your Patients About Aducanumab
    • Advocacy and Payer Relations
  • Neurology Podcast - Over 16 million downloads!
    Neurodegeneration in Pro Football Players: ALS
    In the first part of our two-part series on neurodegeneration in professional football players, Dr. Shuvro Roy talks with Dr. Ann McKee about the high incidence and mortality rates of amyotrophic lateral sclerosis (ALS) in NFL athletes.
    May 19, 2022
    Neurology, Journal, Podcast
    Listen14:42
    Subscribe
    View Recent Podcasts
Site Logo
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise